COPD Exacerbation Biomarker Detection for Targeted Antibiotic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COPD exacerbations often involve sub-optimal antibiotic use, as clinicians lack clear indicators for bacterial infections, leading to inappropriate antibiotic prescriptions and potential antibiotic resistance, highlighting the need for personalized medicine approaches using biomarkers.
Innovation Solution
Measuring cytokine biomarkers IL-1α and TNF-α in biological samples to differentiate between bacterial and non-bacterial exacerbations of COPD, allowing for targeted antibiotic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are prescribed for COPD exacerbations without bacterial infection confirmation, then treatment coverage is broad, but antibiotic resistance increases and treatment accuracy decreases
Solution Approach 1:
The patent replaces the mechanical system of empirical antibiotic prescribing with a biological detection system using cytokine biomarkers (IL-1α and TNF-α) to identify bacterial infections. This substitution enables precise targeting of antibiotics only when biomarkers indicate bacterial etiology, thereby improving treatment accuracy and reducing unnecessary antibiotic use that drives resistance.
Solution Approach 2:
The patent introduces cytokine biomarkers (IL-1α and TNF-α) as intermediary indicators to mediate between the clinical presentation of COPD exacerbation and the decision to prescribe antibiotics. These biomarkers serve as a diagnostic bridge that confirms bacterial infection before antibiotic intervention, resolving the contradiction between broad treatment coverage and targeted precision.
2Adaptability or versatility
If biomarker testing is implemented for COPD exacerbation assessment, then treatment personalization improves, but measurement complexity increases
Solution Approach 1:
The patent extracts and focuses on only two specific cytokine biomarkers (IL-1α and TNF-α) that are most indicative of bacterial infection in COPD exacerbations. By isolating these key markers rather than measuring all possible biomarkers, the system achieves effective treatment personalization while keeping the measurement process relatively simple and clinically feasible.
Solution Approach 2:
The patent changes the diagnostic parameter from traditional clinical symptoms to specific biomarker concentrations (IL-1α and TNF-α levels). This parameter transformation enables objective differentiation between bacterial and non-bacterial exacerbations, facilitating personalized treatment decisions without requiring complex multi-parameter assessment systems.
3Speed
If empirical antibiotic treatment is used for COPD exacerbations, then treatment speed is fast, but treatment appropriateness decreases
Solution Approach 1:
The patent performs preliminary biomarker testing (IL-1α and TNF-α measurement) before initiating antibiotic treatment. This preliminary action identifies bacterial infections in advance, allowing clinicians to prescribe antibiotics only when indicated, thus maintaining rapid treatment response while ensuring appropriateness based on confirmed diagnostic criteria.
Data Source
AI summary
The present invention relates to antibiotic agents for use in the treatment of patients presenting with an exacerbation of chronic obstructive pulmonary disease (COPD). More particularly the present invention relates to antibiotic agents for use in the treatment of COPD exacerbations in patients that, through analysis, have been identified as having an increased concentration of the IL-1α and TNF-α cytokine biomarkers in a biological sample taken from said patient. The present invention is further directed to methods of diagnosing and methods of treating a patient presenting with an exacerbation of COPD, said methods including identifying 1 the patient is suffering from an exacerbation that is associated with a bacterial infection.